



# Department of Health

**ANDREW M. CUOMO**  
Governor

**HOWARD A. ZUCKER, M.D., J.D.**  
Commissioner

**SALLY DRESLIN, M.S., R.N.**  
Executive Deputy Commissioner

## Medicaid Fee- for- Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

Effective **10/03/2019**, the following changes will be made to the Dispense Brand Name Drug when Less Expensive than the Generic Program:

- **Diclegis** will be **ADDED** to the program
- **Delzicol, Eplusa, Kitabis, Proventil HFA, Remodulin, Trizivir, Vesicare** and **Zyflo CR** will be **REMOVED** from the program.

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- **Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription.**
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

### IMPORTANT BILLING INFORMATION

Prescription claims submitted to the Medicaid program **do not require** the submission of Dispense as Written/Product Selection Code of '1'; **Pharmacies can submit any valid NCPDP field (408-D8) value.**

#### List of Brand Name Drugs included in this program\* (updated 09/18/2019)

Aggrenox	Focalin XR	Retin-A cream
Alphagan P 0.15%	Fosrenol chew tablet	Sensipar
Androgel pump & packets	Letairis	Suboxone film
Butrans	Lexiva Tablet	Tegretol suspension
Catapres-TTS	Mitigare	Tracleer tablet
Cellcept suspension	Norvir tablet	Transderm-Scop
Copaxone 20mg	ProAir HFA	Voltaren Gel
<b>Diclegis</b>	Protopic	Xeloda
Elidel	Rapamune solution	Zovirax cream
Exelon Patch	Renagel	Zytiga

\*List is subject to change

**Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs, promoting the use of the most cost-effective product.**